{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:42:38Z","timestamp":1793824958127,"version":"4.6.1"},"reference-count":70,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"am","delay-in-days":387,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.beem.2022.101668","type":"journal-article","created":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T12:19:54Z","timestamp":1651839594000},"page":"101668","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Immune checkpoint inhibitor-related hypophysitis"],"prefix":"10.1016","volume":"36","author":[{"given":"Tadashi","family":"Mizukoshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Fukuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6127","key":"10.1016\/j.beem.2022.101668_bib1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/328267a0","article-title":"A\u00a0new member of the immunoglobulin superfamily--CTLA-4","volume":"328","author":"Brunet","year":"1987","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.beem.2022.101668_bib2","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/intimm\/8.5.765","article-title":"Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes","volume":"8","author":"Agata","year":"1996","journal-title":"Int Immunol"},{"key":"10.1016\/j.beem.2022.101668_bib3","article-title":"Ipilimumab-induced hypophysitis: review of the literature","volume":"38","author":"Araujo","year":"2015","journal-title":"J\u00a0Endocrinol Invest"},{"issue":"19","key":"10.1016\/j.beem.2022.101668_bib4","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6382","key":"10.1016\/j.beem.2022.101668_bib5","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.beem.2022.101668_bib6","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events Associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"42","key":"10.1016\/j.beem.2022.101668_bib7","doi-asserted-by":"crossref","first-page":"11919","DOI":"10.1073\/pnas.1611421113","article-title":"Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities","volume":"113","author":"Subudhi","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beem.2022.101668_bib8","article-title":"Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies","author":"Sullivan","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.beem.2022.101668_bib9","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ecl.2014.10.011","article-title":"Hypophysitis","volume":"44","author":"Fukuoka","year":"2015","journal-title":"Endocrinol metab Clin North Am"},{"issue":"5","key":"10.1016\/j.beem.2022.101668_bib10","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/er.2004-0011","article-title":"Autoimmune hypophysitis","volume":"26","author":"Caturegli","year":"2005","journal-title":"Endocr Rev"},{"issue":"11","key":"10.1016\/j.beem.2022.101668_bib11","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.4049\/jimmunol.2001073","article-title":"Th17 cells Contribute to the Pathology of autoimmune hypophysitis","volume":"206","author":"Chalan","year":"2021","journal-title":"J\u00a0Immunol"},{"issue":"230","key":"10.1016\/j.beem.2022.101668_bib12","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"issue":"12","key":"10.1016\/j.beem.2022.101668_bib13","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1016\/j.ajpath.2016.08.020","article-title":"Hypophysitis Secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: Insights into Pathogenesis from an autopsy series","volume":"186","author":"Caturegli","year":"2016","journal-title":"Am J Pathol"},{"issue":"5","key":"10.1016\/j.beem.2022.101668_bib14","doi-asserted-by":"crossref","first-page":"e002493","DOI":"10.1136\/jitc-2021-002493","article-title":"Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint inhibitors","volume":"9","author":"Kobayashi","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"12","key":"10.1016\/j.beem.2022.101668_bib15","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1007\/s00262-021-02955-y","article-title":"Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome","volume":"70","author":"Kanie","year":"2021","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"10.1016\/j.beem.2022.101668_bib16","doi-asserted-by":"crossref","first-page":"R59","DOI":"10.1530\/EJE-19-1051","article-title":"Mechanisms in endocrinology: autoimmune hypopituitarism: novel mechanistic insights","volume":"182","author":"Takahashi","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2022.101668_bib17","doi-asserted-by":"crossref","DOI":"10.1210\/endrev\/bnz003","article-title":"Autoimmune pituitary disease: new concepts with clinical implications","volume":"41","author":"Yamamoto","year":"2020","journal-title":"Endocr Rev"},{"key":"10.1016\/j.beem.2022.101668_bib18","first-page":"101601","article-title":"Paraneoplastic autoimmune hypophysitis: An emerging concept","author":"Bando","year":"2021","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2022.101668_bib19","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1172\/JCI44073","article-title":"Adult combined GH, prolactin, and TSH deficiency associated with circulating PIT-1 antibody in humans","volume":"121","author":"Yamamoto","year":"2011","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.beem.2022.101668_bib20","doi-asserted-by":"crossref","first-page":"43060","DOI":"10.1038\/srep43060","article-title":"A\u00a0novel thymoma-associated autoimmune disease: anti-PIT-1 antibody syndrome","volume":"7","author":"Bando","year":"2017","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.beem.2022.101668_bib21","article-title":"Two Cases of anti-PIT-1 hypophysitis Exhibited as a Form of paraneoplastic Syndrome not associated with thymoma","volume":"5","author":"Kanie","year":"2020","journal-title":"J\u00a0Endocr Soc"},{"issue":"5","key":"10.1016\/j.beem.2022.101668_bib22","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s11102-018-0901-7","article-title":"Isolated adrenocorticotropic hormone deficiency as a form of paraneoplastic syndrome","volume":"21","author":"Bando","year":"2018","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2022.101668_bib23","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s11102-019-00978-4","article-title":"Ipilimumab-induced hypophysitis, a single academic center experience","volume":"22","author":"Snyders","year":"2019","journal-title":"Pituitary"},{"issue":"2","key":"10.1016\/j.beem.2022.101668_bib24","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1530\/EJE-14-0845","article-title":"Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma","volume":"172","author":"Albarel","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2022.101668_bib25","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2022.101668_bib26","doi-asserted-by":"crossref","first-page":"836859","DOI":"10.3389\/fonc.2022.836859","article-title":"Immune checkpoint inhibitor-induced hypophysitis and patterns of loss of pituitary function","volume":"12","author":"Jessel","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.beem.2022.101668_bib27","series-title":"South Dartmouth (MA): MDText.com, Inc.","author":"Feingold","year":"2000"},{"issue":"1","key":"10.1016\/j.beem.2022.101668_bib28","doi-asserted-by":"crossref","first-page":"1748982","DOI":"10.1080\/2162402X.2020.1748982","article-title":"Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis","volume":"9","author":"Shulgin","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.beem.2022.101668_bib29","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med"},{"issue":"5","key":"10.1016\/j.beem.2022.101668_bib30","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1470-2045(17)30231-0","article-title":"Ipilimumab 10 mg\/kg versus ipilimumab 3 mg\/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial","volume":"18","author":"Ascierto","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beem.2022.101668_bib31","doi-asserted-by":"crossref","DOI":"10.1186\/s40842-018-0073-4","article-title":"Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports","author":"Tan","year":"2019","journal-title":"Clinical Diabetes and Endocrinology"},{"issue":"7","key":"10.1016\/j.beem.2022.101668_bib32","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"10.1016\/j.beem.2022.101668_bib33","doi-asserted-by":"crossref","first-page":"R107","DOI":"10.1530\/EJE-19-0169","article-title":"Management OF endocrine disease: Immune check point inhibitors-induced hypophysitis","volume":"181","author":"Albarel","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"10.1016\/j.beem.2022.101668_bib34","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"99","author":"Faje","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.beem.2022.101668_bib35","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1158\/1078-0432.CCR-14-2353","article-title":"Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study","volume":"21","author":"Min","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.beem.2022.101668_bib36","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/pin.13161","article-title":"An autopsy case study of lymphocytic hypophysitis induced by nivolumab treatment for esophageal malignant melanoma","volume":"71","author":"Okabe","year":"2021","journal-title":"Pathol Int"},{"issue":"11","key":"10.1016\/j.beem.2022.101668_bib37","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1210\/jc.2015-2702","article-title":"HLA markers DQ8 and DR53 are associated with lymphocytic Hypophysitis and may Aid in differential diagnosis","volume":"100","author":"Heaney","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.beem.2022.101668_bib38","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/cen.14082","article-title":"Comparative analysis of human leucocyte antigen between idiopathic and anti-PD-1 antibody induced isolated adrenocorticotropic hormone deficiency: a pilot study","volume":"91","author":"Inaba","year":"2019","journal-title":"Clin Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2022.101668_bib39","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. s.l","volume":"21","author":"Ryder","year":"2014","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"10.1016\/j.beem.2022.101668_bib40","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","article-title":"Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights","volume":"19","author":"Faje","year":"2016","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2022.101668_bib41","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejca.2019.03.002","article-title":"Immune checkpoint inhibitor-associated hypophysitis-World Health Organisation VigiBase report analysis","volume":"113","author":"Guerrero","year":"2019","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.beem.2022.101668_bib42","doi-asserted-by":"crossref","first-page":"e000779","DOI":"10.1136\/jitc-2020-000779","article-title":"Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study","volume":"8","author":"Kobayashi","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"6","key":"10.1016\/j.beem.2022.101668_bib43","doi-asserted-by":"crossref","first-page":"101371","DOI":"10.1016\/j.beem.2019.101371","article-title":"Hypophysitis: An update on the novel forms, diagnosis and management of disorders of pituitary inflammation","volume":"33","author":"Gubbi","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"issue":"1","key":"10.1016\/j.beem.2022.101668_bib44","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1530\/EJE-21-0760","article-title":"Characterisation of the onset and severity of adrenal and thyroid dysfunction associated with CTLA4-related hypophysitis","volume":"186","author":"Seejore","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2022.101668_bib45","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.annemergmed.2016.03.048","article-title":"Pituitary dysfunction: a case series of immune checkpoint inhibitor-related hypophysitis in an Emergency Department","volume":"68","author":"Miller","year":"2016","journal-title":"Annals of Emer Med"},{"issue":"4","key":"10.1016\/j.beem.2022.101668_bib46","first-page":"527","article-title":"Isolated Adrenocorticotropin deficiency due to nivolumab-induced hypophysitis in a patient with advanced lung adenocarcinoma: a case report and literature review","volume":"57","author":"Ohara","year":"2018","journal-title":"s.l. : Intern Med"},{"issue":"4","key":"10.1016\/j.beem.2022.101668_bib47","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/s11102-021-01141-8","article-title":"Isolated ACTH deficiency induced by cancer immunotherapy: a systematic review","volume":"24","author":"Iglesias","year":"2021","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2022.101668_bib48","first-page":"285","article-title":"Refractory hypotension due to Nivolumab-induced adrenal insufficiency","volume":"80","author":"Tsukizawa","year":"2018","journal-title":"Nagoya J Med Sci"},{"issue":"2","key":"10.1016\/j.beem.2022.101668_bib49","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction Following the Use of different immune checkpoint inhibitor regimens: a systematic Review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.beem.2022.101668_bib50","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr Rev"},{"key":"10.1016\/j.beem.2022.101668_bib51","doi-asserted-by":"crossref","first-page":"582394","DOI":"10.3389\/fonc.2020.582394","article-title":"Case report: ipilimumab-induced panhypophysitis: an infrequent Occurrence and literature review","volume":"10","author":"Barnabei","year":"2020","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.beem.2022.101668_bib52","first-page":"1683","article-title":"MRI Findings of immune checkpoint inhibitor-induced hypophysitis: possible Association with fibrosis","volume":"41","author":"Kurokawa","year":"2020","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.beem.2022.101668_bib53","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1210\/jc.2012-4075","article-title":"Endocrine side effects induced by immune checkpoint inhibitors","volume":"98","author":"Corsello","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101668_bib54","first-page":"19","article-title":"Clinical heterogeneity of hypophysitis secondary to PD-1\/PD-L1 blockade: insights from four cases","author":"Lupi","year":"2019","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"10.1016\/j.beem.2022.101668_bib55","first-page":"95","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J\u00a0Immun Cancer"},{"issue":"7","key":"10.1016\/j.beem.2022.101668_bib56","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1530\/ERC-20-0513","article-title":"Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns","volume":"28","author":"Nguyen","year":"2021","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"10.1016\/j.beem.2022.101668_bib57","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.radcr.2018.03.011","article-title":"Ipilimumab cystic hypophysitis mimicking metastatic melanoma","volume":"13","author":"Wallace","year":"2018","journal-title":"Radiol Case Rep"},{"issue":"10","key":"10.1016\/j.beem.2022.101668_bib58","doi-asserted-by":"crossref","first-page":"R207","DOI":"10.1530\/EC-20-0342","article-title":"Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review","volume":"9","author":"Stelmachowska-Bana\u015b","year":"2020","journal-title":"Endocr Connect"},{"issue":"11","key":"10.1016\/j.beem.2022.101668_bib59","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1210\/jc.2016-2118","article-title":"Hormonal Replacement in Hypopituitarism in adults: an endocrine society clinical practice guideline","volume":"101","author":"Fleseriu","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101668_bib60","series-title":"Full prescribing information for Yervoy (ipilimumab)","author":"Squibb Bristol-Myers","year":"2018"},{"issue":"17","key":"10.1016\/j.beem.2022.101668_bib61","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"National comprehensive cancer network. Management of immune-related adverse Events in patients treated with immune checkpoint inhibitor therapy: American Society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beem.2022.101668_bib62","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1002\/cncr.31629","article-title":"High- dose glucocorticoids for the treatment of ipilimumab- induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.beem.2022.101668_bib63","doi-asserted-by":"crossref","first-page":"163","DOI":"10.7861\/clinmed.2018-0440","article-title":"Glucocorticoid use and complications following immune checkpoint inhibitor use in melanoma","volume":"20","author":"Agarwal","year":"2020","journal-title":"Clin Med"},{"issue":"7","key":"10.1016\/j.beem.2022.101668_bib64","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1507\/endocrj.EJ19-0163","article-title":"Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society","volume":"66","author":"Arima","year":"2019","journal-title":"Endocr J"},{"key":"10.1016\/j.beem.2022.101668_bib65","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1158\/1078-0432.CCR-07-0187","article-title":"Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade","volume":"13","author":"Downey","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.beem.2022.101668_bib66","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1530\/EJE-17-0810","article-title":"The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma","volume":"178","author":"Scott","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2022.101668_bib67","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00432-018-2805-3","article-title":"Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis","volume":"145","author":"Ricciuti","year":"2019","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"1","key":"10.1016\/j.beem.2022.101668_bib68","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jdermsci.2017.10.009","article-title":"Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: analysis of 60 Japanese patients","volume":"89","author":"Fujisawa","year":"2018","journal-title":"J\u00a0Dermatol Sci"},{"issue":"5","key":"10.1016\/j.beem.2022.101668_bib69","doi-asserted-by":"crossref","first-page":"e0216954","DOI":"10.1371\/journal.pone.0216954","article-title":"Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab","volume":"14","author":"Yamauchi","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.beem.2022.101668_bib70","first-page":"17","article-title":"Endocrine adverse events related to immune-oncology agents: retrospective experience of a single institution","volume":"12","author":"Espa\u00f1a","year":"2019","journal-title":"Transl Lung Cancer Res"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X22000550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X22000550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:58:48Z","timestamp":1761497928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X22000550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S1521690X22000550"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2022.101668","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibitor-related hypophysitis","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2022.101668","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101668"}}